SynCon® HIV vaccines

T4 and HIV

Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. HIV is divided into two distinct types, HIV-1 and HIV-2, which display biological and clinical distinctions. Most HIV research focuses on type 1.

There are six HIV-1 subtypes, or clades: A, B, C, D, E and AE. Inovio has completed preliminary studies focused on HIV vaccine PENNVAX®-B targeting clade B to achieve proof of principle in generating immune responses. We have incorporated the knowledge from this HIV program into the design of our multi-clade PENNVAX®-GP vaccine, which is now our lead preventive and therapeutic vaccine that broadly targets global HIV strains.



HIV map image

Candidate Geographic Focus Target Envelope Clades Target Antigens Collaborator
PENNVAX®-B North America
Western Europe
Clade B Gag, pol, env Prophylactic study: HIV Vaccine Trials
Network (HVTN)
Therapeutic study: U. of Pennsylvania
PENNVAX®-G Developing regions of Africa and Asia Clades A, C, D Gag, env USMHRP/NIAID
PENNVAX®-GP Developing regions of Africa and Asia Clades A, C, B Gag, env, pol NIH/NIAID/HVTN